RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: JAN VAN DROOGENBROECK

June 2021 Editor's pick Jolien Blokken

OUTCOMES IN  PATIENTS TREATED WITH CAR-T THERAPY WHO WERE ADMITTED TO  INTENSIVE CARE

Side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) often occur after the administration of chimeric antigen receptor (CAR)-T cell therapy and frequently require intensive care unit admission. The international CARRTAS study describes the management and outcomes of critically ill CAR-T recipients in intensive care... 

Read more

INTENSIFIED TREATMENT FOR PATIENTS WITH EARLY STAGE, UNFAVOURABLE HODGKIN’S LYMPHOMA

A long-term analysis of the GHSG HD14 trial confirms the superior tumour control with escalated BEACOPP plus two cycles of ABVD compared to four cycles of ABVD. As there is no difference regarding second primary malignancies between both regimens, the intensified treatment regimen might spare a significant number of patients from the burden of relapse and additional treatment without increased long-term toxicity… 

Read more

CHEMOTHERAPY OR ALLOGENEIC TRANSPLANTATION IN HIGH-RISK PHILADELPHIA CHROMOSOME-NEGATIVE ADULT LYMPHOBLASTIC LEUKAEMIA

The need for allogeneic haematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukaemia (ALL) with high-risk features and adequate measurable residual disease (MRD) clearance remains unclear. Therefore, the ALL-HR-11 trial aimed to evaluate the outcomes of these patients following chemotherapy or allo-HSCT… 

Read more

SALVAGE AUTOLOGOUS TRANSPLANT AND LENALIDOMIDE MAINTENANCE VERSUS LENALIDOMIDE/DEXAMETHASONE FOR RELAPSED MULTIPLE MYELOMA

Although widely used in clinical practice, the role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment remains to be defined. The ReLApsE trial is the first randomised trial to compare these treatment options until disease progression… 

Read more

ADDITION OF LENALIDOMIDE TO R-CHOP IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

Lenalidomide has long been a prime candidate for combination with chemo-immunotherapy in the frontline treatment of diffuse large B-cell lymphoma (DLBCL). The phase II ECOG ACRIN E1412 study now demonstrates that the addition of lenalidomide to R-CHOP (R2CHOP) indeed improves the outcome of newly diagnosed DLBCL patients, including patients with activated B-cell-like subtype… 

Read more

X